Genprex, Inc.

NasdaqCM:GNPX 주식 보고서

시가총액: US$4.0m

Genprex 관리

관리 기준 확인 3/4

Genprex CEO는 Ryan Confer, Sep2016 에 임명되었습니다 의 임기는 8.17 년입니다. 는 $ 7.37K 가치에 해당하는 회사 주식의 0.19% 직접 소유합니다. 7.37K. 경영진과 이사회의 평균 재임 기간은 각각 3.2 년과 4.3 년입니다.

주요 정보

Ryan Confer

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기8.2yrs
CEO 소유권0.2%
경영진 평균 재임 기간3.2yrs
이사회 평균 재임 기간4.3yrs

최근 관리 업데이트

Recent updates

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Aug 16
Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Jan 31
Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Oct 12
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14
We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27
We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11
Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

May 05

Genprex' stock jumps after corporate update

Feb 01

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Jan 13

Genprex completes manufacturing scale-up of lung cancer therapy

Dec 22

CEO 보상 분석

Ryan Confer 의 보수는 Genprex 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$23m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023n/an/a

-US$31m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$1mUS$393k

-US$24m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$1mUS$345k

-US$21m

Sep 30 2021n/an/a

-US$19m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$1mUS$351k

-US$18m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$1mUS$300k

-US$11m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$11m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$2mUS$225k

-US$12m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$8m

Mar 31 2018n/an/a

-US$3m

Dec 31 2017US$585kUS$180k

-US$3m

보상 대 시장: US 시장에서 비슷한 규모의 회사에 비해 Ryan 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Ryan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Ryan Confer (42 yo)

8.2yrs

테뉴어

US$1,135,943

보상

Mr. Ryan M. Confer, M.S. has been the Chief Financial Officer of Genprex, Inc. since September 2016 and serves as its Chief Executive Officer, President and Director since May 08, 2024. Mr. Confer has serv...

리더십 팀

이름위치테뉴어보상소유권
Mark Berger
Chief Medical Officer3.2yrsUS$947.11k0.048%
$ 1.9k
Ryan Confer
President8.2yrsUS$1.14m0.19%
$ 7.4k
David Schloss
Senior Vice President of Human Resources2.8yrs데이터 없음데이터 없음
Thomas Gallagher
Senior Vice President of Intellectual Property & Licensing4.2yrs데이터 없음데이터 없음
Suzanne Thornton-Jones
Senior Vice President of Regulatory Affairs & Quality1.3yrs데이터 없음데이터 없음
Jack Roth
Chairman of Scientific & Medical Advisory Boardno data데이터 없음데이터 없음

3.2yrs

평균 재임 기간

경험이 풍부한 관리: GNPX 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Ryan Confer
Presidentless than a yearUS$1.14m0.19%
$ 7.4k
Jack Roth
Chairman of Scientific & Medical Advisory Boardno data데이터 없음데이터 없음
Brent Longnecker
Independent Director4.7yrsUS$161.61k0.024%
$ 962.7
James E. Rothman
Strategic Advisor to the Board of Directors12.3yrs데이터 없음데이터 없음
Pasi Antero Janne
Member of Scientific & Medical Advisory Boardno data데이터 없음데이터 없음
George Peoples
Member of Clinical Advisory Board3.8yrs데이터 없음데이터 없음
Shu Kam Mok
Member of Scientific & Medical Advisory Boardno data데이터 없음데이터 없음
George Simon
Member of Scientific & Medical Advisory Boardno data데이터 없음데이터 없음
William Wilson
Independent Director4.7yrsUS$151.16k0%
$ 0
Jose Antonio Toscano
Independent Non-Executive Chairman4.7yrsUS$161.61k0%
$ 0
George Gittes
Member of Scientific Advisory Board4yrs데이터 없음데이터 없음
Michael Morse
Member of Clinical Advisory Board3.8yrs데이터 없음데이터 없음

4.3yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: GNPX 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.